Vertex Reports Full-Year and Fourth Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
No Surprises from Vertex (VRTX) But Piper Jaffray Moves Price Target Down to $143
January 28, 2016 7:25 AM ESTPiper Jaffray analyst Edward Tenthoff reiterated an Overweight rating but lowered his price target on Vertex (NASDAQ: VRTX) to $143.00 (from $180.00) following results which offered no surprises.
Tenthoff commented, "As pre-announced, >4,500 patients began ORKAMBI in the U.S. resulting in sales of $220 million in 4Q:15;... More
Vertex Pharma (VRTX) Reports In-Line Q4 EPS
January 27, 2016 4:03 PM ESTVertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $0.17, in-line with the analyst estimate of $0.17. Revenue for the quarter came in at $417.94 million versus the consensus estimate of $406.3 million.
"Entering 2016, Vertex is in a strong financial position to support continued investment in our business to create future medicines for serious diseases and value for our shareholders," said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. "We look forward... More
